SofWave Medical (SOFW) Stifel 2024 Healthcare Conference summary

Market and business overview

• Non-invasive ultrasound technology with strong IP and broad FDA clearances is driving global expansion, now in over 40 countries with direct sales in the U.S. and U.K.

• Management team has decades of experience, previously building market leaders and executing global launches.

• Brand awareness and digital marketing are prioritized, with 25% of revenue invested in these efforts and a focus on influencer marketing.

• Business model combines capital equipment sales with recurring consumable revenue, supported by a frictionless e-store and IoT-enabled devices.

• Customer ROI is a key selling point, with average payback in 4–6 months and high satisfaction rates among providers.

Product innovation and differentiation

• Technology delivers parallel ultrasound stimulation to the mid-dermis, minimizing downtime and complications compared to alternatives.

• Eight FDA clearances cover a range of indications, including eye lift, jawline, submental area, acne scars, and cellulite.

• Recent launch of a 4th-gen muscle toning device that mimics functional exercise, expanding the product line.

• Devices are IoT-enabled, supporting seamless consumable purchases and usage tracking.

• Differentiation from commoditized competitors is maintained through superior results, durable treatments, and strong brand support.

Financial performance and growth

• Q3 revenue reached $13.5 million, up over 10% year-over-year, with recurring revenue growing over 70% year-over-year.

• Year-to-date revenue (Jan–Sep) was $41.3 million, representing 18% year-over-year growth.

• Gross margin stands at 75.3%, driven by high-margin consumables and solid device margins.

• Over 385,000 treatments sold since launch, with 85% CAGR since 2020 and over $50 million revenue in 2023.

• Cash flow positive in Q3, with over $21 million in the bank and significant reductions in operating expenses and losses.